Michael Hemphill, MD
Hematology & Oncology · Hermitage, TNNPI 1902812571
Payments from drug & device makers
Across 663 payments — averaging $229.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$45K
- Eli Lilly$29K
- Sanofi$24K
- Astellas Pharma Global Development$14K
- AstraZeneca$8K
- Biogen$7K
- plus $25K from 54 others
Across 1 payment — averaging $22.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$22
What the payments were for
- Consulting fees$56,15462%
- Speaking & faculty fees$17,88320%
- Travel & lodging$1,8582%
- Food & beverage$14,21116%
- Education$3270%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$152,441 in reported general payments places this provider in the 70th percentile of 251 hematology & oncology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 62 | $1,042,649 |
| BrukinsaZanubrutinib | 61 | $627,624 |
| IbrancePalbociclib | 25 | $391,379 |
| PromactaEltrombopag Olamine | 22 | $373,108 |
| JakafiRuxolitinib Phosphate | 19 | $341,205 |
| ImbruvicaIbrutinib | 19 | $287,355 |
| CalquenceAcalabrutinib Maleate | 18 | $245,393 |
| LynparzaOlaparib | 12 | $191,803 |
| KisqaliRibociclib Succinate | 11 | $177,144 |
| XareltoRivaroxaban | 95 | $68,235 |
| EliquisApixaban | 60 | $44,069 |
| Imatinib Mesylate | 13 | $39,055 |
| Anastrozole | 194 | $3,402 |
| Exemestane | 17 | $3,211 |
| Tamoxifen Citrate | 76 | $2,071 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $515 | $1,042,64962 claims |
| Beigene USA, Inc.Brukinsa | $70 | $627,62461 claims |
| NovartisPromacta, Kisqali | $1,278 | $550,25133 claims |
| AstraZenecaCalquence, Lynparza | $8,144 | $437,19630 claims |
| PfizerIbrance, Eliquis | $368 | $435,44985 claims |
| Incyte CorporationJakafi | $903 | $341,20519 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $51 | $287,35519 claims |
| Johnson & JohnsonXarelto | $507 | $68,23595 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $62 | $53660 claims |
| Lilly USA, LLCOlanzapine | $154 | $24631 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 251 hematology & oncology providers in Tennessee.
Other hematology & oncology in Hermitage
- Laura BlakelyHermitage$2.2M
- Erika HamiltonNashville$45.4M
- Ian FlinnNashville$41.2M
- Johanna BendellNashville$28.5M
- Jesus BerdejaNashville$22.2M
- Meredith McKeanNashville$16M
- Krish PatelNashville$14.2M
- Kathryn BeckermannFranklin$13.6M
- Denise YardleyNashville$13.2M
- Todd BauerNashville$10.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.